Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines
Giacomo Bregni(Institut Jules Bordet), Francesco Sclafani(Royal Marsden NHS Foundation Trust), Chiara Baratelli(University of Turin), Tuğba Akın Telli(Université Libre de Bruxelles), Alain Hendlisz(London Cancer), Amélie Deleporte(Université Libre de Bruxelles), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Leila Shaza(Clinique Saint Jean), Gabriel Liberale(Institut Jules Bordet), L. Moretti(Université Libre de Bruxelles), Silvia Camera(Vita-Salute San Raffaele University)
Cited by 19
Related Papers
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
|Journal of Crohn s and Colitis|2013|669
Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors
|The Oncologist|2007|421
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
|JNCI Journal of the National Cancer Institute|2019|299